標(biāo)題: Titlebook: Cell Therapy for Perinatal Brain Injury; Haruo Shintaku,Akira Oka,Makoto Nabetani Book 2018 Springer Nature Singapore Pte Ltd. 2018 Stem c [打印本頁] 作者: 憑票入場 時間: 2025-3-21 17:57
書目名稱Cell Therapy for Perinatal Brain Injury影響因子(影響力)
書目名稱Cell Therapy for Perinatal Brain Injury影響因子(影響力)學(xué)科排名
書目名稱Cell Therapy for Perinatal Brain Injury網(wǎng)絡(luò)公開度
書目名稱Cell Therapy for Perinatal Brain Injury網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cell Therapy for Perinatal Brain Injury被引頻次
書目名稱Cell Therapy for Perinatal Brain Injury被引頻次學(xué)科排名
書目名稱Cell Therapy for Perinatal Brain Injury年度引用
書目名稱Cell Therapy for Perinatal Brain Injury年度引用學(xué)科排名
書目名稱Cell Therapy for Perinatal Brain Injury讀者反饋
書目名稱Cell Therapy for Perinatal Brain Injury讀者反饋學(xué)科排名
作者: 失望昨天 時間: 2025-3-21 23:40 作者: 上釉彩 時間: 2025-3-22 01:08
Pathophysiology and Pathology of Neonatal Hypoxic-Ischemic Encephalopathy,unique. The mode of cell death includes necrosis and apoptosis. Necrosis occurs in conditions of primary energy failure following the initial injury. On the other hand, apoptosis occurs days after the initial injury. The damaged area in the brain depends on the mode of injury. Severe and prolonged i作者: 尾隨 時間: 2025-3-22 06:37 作者: 鑲嵌細(xì)工 時間: 2025-3-22 09:37
Hematopoietic Stem Cells for Perinatal Brain Injury,r cell-based therapies for perinatal brain injury. Nearly 20 studies in models of perinatal brain injury, most of which are rodent models of neonatal hypoxia-ischemia, have histologically and functionally demonstrated beneficial effects of systemic administration of HSCs and the related cell fractio作者: 愛了嗎 時間: 2025-3-22 16:23
Umbilical Cord-Derived Mesenchymal Stromal Cells for Perinatal Brain Injury,ons including (1) no adverse events during collection, (2) ease of collection even after cord blood (CB) collection or failure to collect CB, (3) minimal ethical controversy, (4) multipotency to differentiate into various cell types, and (5) low immunogenicity with significant immunosuppressive abil作者: 愛了嗎 時間: 2025-3-22 17:31
Other Tissues-Derived Mesenchymal Stem Cells for Perinatal Brain Injury, in preclinical models of HIE. However, despite their neural commitment, ethical concerns hinder the use of postmortem human brains as a source of NSPCs in future clinical applications. Furthermore, intracerebral administration is an invasive procedure..Stem cells originating from nonneural tissues 作者: BARK 時間: 2025-3-22 23:03
CD34+ Cell in Cord Blood and Neonates,opoietic and non-hematopoietic stem/progenitor cells. This chapter focuses on recent progresses in stem cell biology on cord blood cells. During embryonic development, expression of CD34 is tightly regulated in a spatial and temporal manner. Subpopulations of CD34. cells in cord blood have been char作者: agonist 時間: 2025-3-23 01:29
The History of Hypothermia Therapy for Perinatal Ischemic Brain Injury,y starts and proceed to Consensus 2010 in which hypothermia therapy should be recommended for newborns with moderate to severe hypoxic-ischemic encephalopathy (HIE). Next I talk about how hypothermia therapy spreads and could be standardized on the guideline and nationwide online registry system in 作者: 侵略主義 時間: 2025-3-23 06:55
Clinical Procedure of Cell Therapy: Cord Blood Collection,ed in the United States (Michael et al. J Pediatr 164:973–979, 2014). We have thus decided to initiate a similar clinical trial in Japan and set obstetric criteria for the indication of cell therapy. Written consent for UCB collection was obtained following successful collection, as the cases includ作者: 不自然 時間: 2025-3-23 11:11
Clinical Procedure of Cell Therapy: Separation and Infusion,plantation in infants with HIE. We selected patients for UCB stem cell transplantation based on following criteria; (1) moderate or severe HIE according to the classification of Sarnat II or III and Thompson score ≥10 points, (2) gestational age ≥36?weeks, (3) body weight at birth >1800?g, (4) born 作者: enumaerate 時間: 2025-3-23 16:53
Cell Therapy for Adult Infarction,overy. Recently, accumulating evidences suggest that neurogenesis occurs even in the adult brain and patients may have a chance for functional recovery after stroke. Although most stroke-induced neural stem cells cannot survive in the poststroke brain, we demonstrated that therapeutic angiogenesis a作者: 非實(shí)體 時間: 2025-3-23 21:16 作者: occult 時間: 2025-3-24 00:47 作者: asthma 時間: 2025-3-24 06:07 作者: Glower 時間: 2025-3-24 08:57
http://image.papertrans.cn/c/image/222890.jpg作者: Apoptosis 時間: 2025-3-24 13:40 作者: minion 時間: 2025-3-24 15:07 作者: 裝勇敢地做 時間: 2025-3-24 20:37 作者: 古代 時間: 2025-3-25 01:09 作者: 作嘔 時間: 2025-3-25 03:25
https://doi.org/10.1007/BFb0040988r cell-based therapies for perinatal brain injury. Nearly 20 studies in models of perinatal brain injury, most of which are rodent models of neonatal hypoxia-ischemia, have histologically and functionally demonstrated beneficial effects of systemic administration of HSCs and the related cell fractio作者: Aids209 時間: 2025-3-25 11:22 作者: Lumbar-Spine 時間: 2025-3-25 15:19 作者: PAD416 時間: 2025-3-25 17:53 作者: 1分開 時間: 2025-3-25 20:16
Helmuth Goldberg,Fredi Tr?ltzschy starts and proceed to Consensus 2010 in which hypothermia therapy should be recommended for newborns with moderate to severe hypoxic-ischemic encephalopathy (HIE). Next I talk about how hypothermia therapy spreads and could be standardized on the guideline and nationwide online registry system in 作者: Virtues 時間: 2025-3-26 01:11
Karl-Heinz Hoffmann,Werner Krabsed in the United States (Michael et al. J Pediatr 164:973–979, 2014). We have thus decided to initiate a similar clinical trial in Japan and set obstetric criteria for the indication of cell therapy. Written consent for UCB collection was obtained following successful collection, as the cases includ作者: tinnitus 時間: 2025-3-26 04:34
https://doi.org/10.1007/BFb0044338plantation in infants with HIE. We selected patients for UCB stem cell transplantation based on following criteria; (1) moderate or severe HIE according to the classification of Sarnat II or III and Thompson score ≥10 points, (2) gestational age ≥36?weeks, (3) body weight at birth >1800?g, (4) born 作者: CANE 時間: 2025-3-26 09:09
Optimization of Discrete Time Systemsovery. Recently, accumulating evidences suggest that neurogenesis occurs even in the adult brain and patients may have a chance for functional recovery after stroke. Although most stroke-induced neural stem cells cannot survive in the poststroke brain, we demonstrated that therapeutic angiogenesis a作者: 惡名聲 時間: 2025-3-26 13:38 作者: 暗諷 時間: 2025-3-26 17:37
Optimization of Discrete Time Systemsurring at delivery or perinatally. To prevent or reduce the neurogenic disabilities in cerebral palsy, therapies using hypothermia, autologous cord blood infusion, and recently, mesenchymal stromal cells (MSCs) have been applied. MSCs can be obtained from fetal appendages such as cord blood, umbilic作者: Mangle 時間: 2025-3-27 00:12
https://doi.org/10.1007/978-981-10-1412-3Stem cell therapy; CD34 cell; Neural stem cell; Mesenchymal stem cell; Ischemic disease; Clinical Trial作者: 動機(jī) 時間: 2025-3-27 02:16 作者: NOMAD 時間: 2025-3-27 05:45
Clinical Trial of Autologous Cord Blood Cell Therapy for Neonatal Hypoxic Ischemic Encephalopathy (gous non-cryopreserved volume- and red blood cell-reduced UCB is the most feasible method for cell therapy, especially when used at the acute phase of acute onset diseases. Fewer than ten clinical studies, including ours, using UCB for newborns with acute brain injury have been reported or listed on作者: muffler 時間: 2025-3-27 12:23
Hematopoietic Stem Cells for Perinatal Brain Injury,therapy with HSCs or the cell fraction containing HSCs has several advantages over other types of cell therapies. This approach does not require intracranial transplantation; intravenous transfusion seems sufficient for them to exert their beneficial effects. The cells are easily obtained, and neith作者: 騷擾 時間: 2025-3-27 15:16
Other Tissues-Derived Mesenchymal Stem Cells for Perinatal Brain Injury,UCBCs in emergency situations..MSCs can be used as alternative cells for the treatment of perinatal HIE because we can use allogeneic MSCs. In this chapter, I describe preclinical studies with various origins of MSCs as well as clinical studies.作者: hurricane 時間: 2025-3-27 17:56
Clinical Procedure of Cell Therapy: Separation and Infusion, a day for 12?h to 3?days..This treatment was successful and safe in all three cases with no adverse effects. A randomized phase II study to provide further safety, feasibility, and efficacy information among a wider number of sites is warranted.作者: 拍下盜公款 時間: 2025-3-28 01:17
Cell Therapy for Adult Infarction,garding cell therapy to enhance function recovery and introduces our clinical trial using autologous bone marrow mononuclear cells for adult patients with cerebral infarction. We also refer to a future strategy of cell therapy that aims to support ideal regenerative process after stroke in the adult作者: 牛馬之尿 時間: 2025-3-28 05:37
Clinical Trials on Cell Therapy for Perinatal Brain Injury: Challenges and Opportunities,nt of new drugs. For instance, the Pharmaceuticals and Medical Devices Agency (PMDA) has established a special department for cellular and tissue-based products; furthermore, the PMDA has launched a conditional time-limited marketing authorization system. This system makes it possible to rapidly pro作者: Adulterate 時間: 2025-3-28 08:30 作者: moribund 時間: 2025-3-28 12:03 作者: MUT 時間: 2025-3-28 17:52 作者: 大洪水 時間: 2025-3-28 19:18 作者: Patrimony 時間: 2025-3-29 02:22 作者: 反對 時間: 2025-3-29 06:09
Optimization of Discrete Time Systemsgarding cell therapy to enhance function recovery and introduces our clinical trial using autologous bone marrow mononuclear cells for adult patients with cerebral infarction. We also refer to a future strategy of cell therapy that aims to support ideal regenerative process after stroke in the adult作者: 慌張 時間: 2025-3-29 07:58
Conclusions and further research,nt of new drugs. For instance, the Pharmaceuticals and Medical Devices Agency (PMDA) has established a special department for cellular and tissue-based products; furthermore, the PMDA has launched a conditional time-limited marketing authorization system. This system makes it possible to rapidly pro作者: 新娘 時間: 2025-3-29 15:26 作者: lethargy 時間: 2025-3-29 18:59 作者: 侵略主義 時間: 2025-3-29 23:06 作者: 顛簸下上 時間: 2025-3-30 03:20 作者: Comedienne 時間: 2025-3-30 06:35
https://doi.org/10.1007/BFb0040988 as that by term newborns with HIE (Touyama et al. Brain Dev 38:792–799, 2016; Koterazawa et al. No to Hattatsu 48:14–19, 2016; Glinianaia et al. Dev Med Child Neurol 59:864–870, 2017). Therefore, we are now promoting a new clinical study protocol of cell therapy for premature newborns with PVL or IVH.作者: 松果 時間: 2025-3-30 11:51 作者: 蘆筍 時間: 2025-3-30 13:37 作者: OCTO 時間: 2025-3-30 16:48
A New Prospective Cell Therapy for Neonatal Brain Injury,ood infusion, and recently, mesenchymal stromal cells (MSCs) have been applied. MSCs can be obtained from fetal appendages such as cord blood, umbilical cord, amnion, and placenta. In this chapter, the expected feasibility of such cell therapies for cerebral palsy is discussed.作者: PACK 時間: 2025-3-30 21:19
Conclusions and further research, in CD34. cells. Proportion of CD34. cells tends to be higher in cord blood from preterm baby. The higher number of circulating CD34. cells in neonate has been found to be linked to the lower risk of prematurity-related complications. Further mechanistic studies will be required to reveal the role of circulating CD34. cells in neonate.
